Dr. Reddy’s Laboratories Limited, one of India’s leading pharmaceutical and biotechnology companies, has consistently delivered strong earnings through innovation and exports. However, as we approach the November 2025 expiry, the stock appears to be entering a short-term corrective phase, offering a potential opportunity for traders to consider short setups.
Technical View (For November 2025 Expiry):
According to the latest technical analysis, Dr. Reddy’s Labs share is showing resistance near ₹1210 levels, indicating mild weakness in momentum.
-
Entry Level: ₹1210
-
Stop Loss: ₹1240
-
Target Price: ₹1175
-
Expiry: November 2025
The stock may face short-term selling pressure if it fails to sustain above ₹1210. Traders can consider short positions for November 2025 expiry, maintaining a strict stop loss at ₹1240 and aiming for a target of ₹1175. RSI and MACD indicators are showing early signs of a bearish crossover, suggesting limited upside in the near term.
About Dr. Reddy’s Laboratories:
Dr. Reddy’s Laboratories Ltd. is a globally recognized Indian multinational pharmaceutical company headquartered in Hyderabad. It manufactures and markets a wide range of generic formulations, active pharmaceutical ingredients (APIs), and biosimilars. The company’s consistent R&D focus and strong export market presence have made it one of India’s most valuable pharma brands.
Expert Insights by Niti Neeyam Services:
Other Financial & Business Services by Niti Neeyam Services:
In addition to share market insights, we provide a complete range of financial and business services such as:
-
GST Registration & Filing
-
ITR Filing (Individual & Business)
-
Auditing & Bookkeeping
-
Tally Accounting & Balance Sheet Preparation
-
Digital Signature (DSC)
-
FSSAI & Trade License Registration
-
Loans – Personal, MSME, Mudra, Home, Car & Loan Against Property
-
Insurance – Two-wheeler, Four-wheeler & General Insurance
-
Demat Account Opening & Share/Commodity/Forex Trading
Visit our official website nitineeyam.in to explore our full range of services and trading subscriptions.
Disclaimer:
This blog post is meant for educational and informational purposes only. It does not constitute financial advice or a solicitation to buy/sell securities. Stock and derivatives trading involve market risks. Please consult a financial advisor before investing or trading.
0 Comments